Get the Stockscreener App
10.37
4.96%
0.49
After Hours:
10.30
-0.07
-0.68%
Tonix Pharmaceuticals Holding Corp stock is traded at $10.37, with a volume of 403.11K.
It is up +4.96% in the last 24 hours and down -21.56% over the past month.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
See More
Previous Close:
$9.88
Open:
$10
24h Volume:
403.11K
Relative Volume:
0.80
Market Cap:
$165.31M
Revenue:
$13.11M
Net Income/Loss:
$-124.02M
P/E Ratio:
-0.7272
EPS:
-14.261
Net Cash Flow:
$-107.25M
1W Performance:
-5.56%
1M Performance:
-21.56%
6M Performance:
-43.52%
1Y Performance:
-79.15%
1-Day Range:
$9.99
$10.58
1-Week Range:
$9.81
$11.78
52-Week Range:
$9.81
$69.97
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
10.37 | 157.50M | 13.11M | -124.02M | -107.25M | -14.26 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
Tonix Pharmaceuticals Holding Corp - TradingKey
Tonix Pharmaceuticals Holding Corp (TNXP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tonix Pharmaceuticals Holding Corp. to Host Second Quarter 2026 Financial Results Conference Call and Webcast - Quiver Quantitative
Tonix to discuss second-quarter results on Aug. 10 call - Stock Titan
TNXP|Tonix Pharmaceuticals Holding Corp|Price:10.390|Chg%:+0.510 - TradingKey
Tonix Pharmaceuticals Holding Corp (TNXP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tonix Pharmaceuticals Holding Corp. Revenue Breakdown – NASDAQ:TNXP - TradingView
Why TNXP Stock Is Suddenly Back On Retail Radar - Stocktwits
Tonix Pharmaceuticals Holding Corp (TNXP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tonix Pharmaceuticals Holding Corp (TNXP) Institutional Confidence - TradingKey
Tonix Pharmaceuticals Holding Corp (TNXP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug - Stocktwits
Total debt per share of Tonix Pharmaceuticals Holding Corp. – GETTEX:TPM0 - TradingView
TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff - Stocktwits
Tonix shares TNX-4800 Lyme disease prevention presentation - Bitget
Tonix Pharmaceuticals (TNXP) Investor presentation Summary - Quartr
Tonix Pharmaceuticals (NASDAQ:TNXP): Can This Penny Stock Deliver? - Kalkine Media
Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models - Sahm
Tonix Pharmaceuticals Announces Publication in the - GlobeNewswire
Precision Trading with Tonix Pharmaceuticals Holding Corp. (TNXP) Risk Zones - Stock Traders Daily
symbol__ Stock Quote Price and Forecast - CNN
Tonix secures Medicare coverage for fibromyalgia drug TONMYA By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals (TNXP) Expands Medicare Coverage for Fibro - GuruFocus
Tonix Expands TONMYA Medicare Coverage with New Payer Agreement (TNXP) - Yahoo Finance
Tonix Pharmaceuticals Secures Major Medicare Deal for TONMYA®, Expanding Fibromyalgia Treatment Access to 145 Million Covered Lives – Minichart - Minichart
Tonix Pharmaceuticals (TNXP) Secures Medicare Coverage for Tonmy - GuruFocus
Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA® - The Manila Times
Tonix Pharmaceuticals Adds Medicare Part D Coverage for TONMYA, Expands Sales Force - TradingView
Tonix secures Medicare coverage for fibromyalgia drug TONMYA - Investing.com
Tonix Pharmaceuticals Announces Major Medicare Coverage Agreement for TONMYA, Expanding U.S. Access to Approximately 145 Million Covered Lives - Quiver Quantitative
Tonix Pharmaceuticals (NASDAQ: TNXP) secures PBM Medicare pact, targeting 145M TONMYA covered lives - Stock Titan
Form 4 Tonix Pharmaceuticals Holding Corp For: 9 July By Investing.com - Investing.com Nigeria
Tonix (NASDAQ: TNXP) CFO adds 1,453 shares through 2025 employee stock plan - Stock Titan
Technical Reactions to TNXP Trends in Macro Strategies - Stock Traders Daily
Tonix: 'Hold' Based On Tonmya Payer Expansions And MDD Trial Initiation - Seeking Alpha
Tonix Pharmaceuticals Holding Corp. has enrolled the first patient in its Phase 2 “HORIZON” study of TNX-102 SL (sublingual tablet) for the treatment of major depressive disorder (MDD). - Bitget
Tonix: Slow Start For Tonmya, Speculative Pipeline Warrants Hold Rating (NASDAQ:TNXP) - Seeking Alpha
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):